Request Demo
Recent blog posts
Latest Hotspot
8 min read
Irinotecan Hydrochloride Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 July 2026
irinotecan: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Efavaleukin alfa Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 July 2026
efavaleukin alfa: Discontinued. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Danicopan Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 July 2026
danicopan: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Diroximel fumarate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 July 2026
diroximel fumarate: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Dimethyl fumarate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 July 2026
dimethyl fumarate: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Caplacizumab-YHDP Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 July 2026
caplacizumab: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Lusutrombopag Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 July 2026
lusutrombopag: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Eltrombopag Diolamine Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 July 2026
eltrombopag: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Emicizumab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 July 2026
emicizumab: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Luspatercept-AAMT Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 July 2026
luspatercept: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Voxelotor Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 July 2026
voxelotor: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Idursulfase Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 July 2026
idursulfase: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.